// App-Quantinova.ai

297 : Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

Researchers

Presenter

  • Louis Bessette

Principal Investigators

  • Adriana Kakehasi

  • Neil Basu

  • David A. Walsh

  • Andra Balanescu

  • Clifton Bingham

  • Andrew Garrison

  • Ivan Lagunes

  • sander strengholt

  • Ralph Lippe

  • Maxime Dougados

Medical Centers

  • University Paris-Sud, Paris, France

  • Centre -Osteoporose et de Rhumatologie de Quebec CORQ, Quebec, QC, Canada

  • University of Nottingham, Nottingham, United Kingdom

  • University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

  • Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil

  • Johns Hopkins University, Baltimore, MD

  • AbbVie, Inc, Wiesbaden, Germany

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • Panama

  • Canada

  • Brazil

  • United Kingdom

  • Romania

  • United States

  • Netherlands

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved